Document is current
Any future updates will be listed below
-
Authors
Nelson, Blessie Elizabeth https://orcid.org/0000-0002-8227-638X
Reddy, Neha K. https://orcid.org/0000-0003-3236-9104
Huse, Jason T.
Amini, Behrang
Nardo, Mirella https://orcid.org/0000-0002-9396-7864
Gouda, Mohamed https://orcid.org/0000-0003-4829-6739
Weathers, Shiao-Pei
Subbiah, Vivek https://orcid.org/0000-0002-6064-6837
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Clinical Center (R01CA273168, R01CA242845)
U.S. Department of Health & Human Services | NIH | NIH Clinical Center
- License Information
-
More Information
Article History
Received: 23 January 2023
Accepted: 12 May 2023
First Online: 25 May 2023
Competing interests
: V.S. reports receiving Research funding/Grant support for clinical trials from Roche/ Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda, and National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning point therapeutics, Boston Pharmaceuticals; Travel support from Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte and has served on Consultancy/Advisory boards for Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED pharma, MedImmune, Novartis, Relay Therapeutics, Roche; Other: Medscape. The remaining authors declare no competing interests.
: Ethical approval/Institutional review board approval for the above clinical trials was obtained by MD Anderson Cancer Center. Consent to participate was obtained.
